Lead Product(s) : Nifekalant Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.
Details : Nifekalant HCl is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tachycardia, Ventricular.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 27, 2019
Lead Product(s) : Nifekalant Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
